75 related articles for article (PubMed ID: 9923826)
1. Safety and potential effectiveness of daunorubicin-containing liposomes in patients with advanced recurrent malignant CNS tumors.
Boiardi A; Pozzi A; Salmaggi A; Eoli M; Zucchetti M; Silvani A
Cancer Chemother Pharmacol; 1999; 43(2):178-9. PubMed ID: 9923826
[No Abstract] [Full Text] [Related]
2. Liposomal daunorubicin (DaunoXome) in children with recurrent or progressive brain tumors.
Lippens RJ
Pediatr Hematol Oncol; 1999; 16(2):131-9. PubMed ID: 10100273
[TBL] [Abstract][Full Text] [Related]
3. Liposomal daunorubicin (DaunoXome) for treatment of relapsed meningeal acute myeloid leukemia.
Piccaluga PP; Visani G; Martinelli G; Isidori A; Malagola M; Rondoni M; Baccarani M; Tura S
Leukemia; 2002 Sep; 16(9):1880-1. PubMed ID: 12200714
[No Abstract] [Full Text] [Related]
4. Pharmacokinetics and tissue distribution of dual-targeting daunorubicin liposomes in mice.
Ying X; Wen H; Yao HJ; Zhang Y; Tian W; Zhang L; Ju RJ; Wang XX; Yu Y; Lu WL
Pharmacology; 2011; 87(1-2):105-14. PubMed ID: 21282968
[TBL] [Abstract][Full Text] [Related]
5. Second-line chemotherapy with the association of liposomal daunorubicin, carboplatin and etoposide in children with recurrent malignant brain tumors.
Fiorillo A; Maggi G; Greco N; Migliorati R; D'Amico A; De Caro MD; Sabbatino MS; Buffardi F
J Neurooncol; 2004 Jan; 66(1-2):179-85. PubMed ID: 15015784
[TBL] [Abstract][Full Text] [Related]
6. Liposomal daunorubicin is not recommended in patients with less than advanced HIV-related Kaposi's sarcoma.
White RM
AIDS; 1997 Sep; 11(11):1412-3. PubMed ID: 9302461
[No Abstract] [Full Text] [Related]
7. DaunoXome shows promise as breast cancer treatment.
Oncology (Williston Park); 1996 Mar; 10(3):425. PubMed ID: 8820459
[No Abstract] [Full Text] [Related]
8. [Administration of liposomal preparation of DaunoXome for breast cancer in patients with poor prognosis].
Darskaia EI; Zubarovskaia LS; Afanas'ev BV
Vopr Onkol; 1999; 45(4):440-4. PubMed ID: 10532108
[TBL] [Abstract][Full Text] [Related]
9. Safety and early efficacy assessment of liposomal daunorubicin (DaunoXome) in adults with refractory or relapsed acute myeloblastic leukaemia: a phase I-II study.
Fassas A; Buffels R; Anagnostopoulos A; Gacos E; Vadikolia C; Haloudis P; Kaloyannidis P
Br J Haematol; 2002 Feb; 116(2):308-15. PubMed ID: 11841431
[TBL] [Abstract][Full Text] [Related]
10. Palmar-plantar erythrodysesthesia syndrome associated with liposomal daunorubicin.
Hui YF; Cortes JE
Pharmacotherapy; 2000 Oct; 20(10):1221-3. PubMed ID: 11034047
[TBL] [Abstract][Full Text] [Related]
11. Antitumor efficacy of Lf modified daunorubicin plus honokiol liposomes in treatment of brain glioma.
Liu S; Zhang SM; Ju RJ; Xiao Y; Wang X; Song XL; Gu LY; Cheng L; Li XT; Chen GR
Eur J Pharm Sci; 2017 Aug; 106():185-197. PubMed ID: 28583810
[TBL] [Abstract][Full Text] [Related]
12. Phase I clinical trial of liposomal daunorubicin in hepatocellular carcinoma complicating liver cirrhosis.
Daniele B; De Vivo R; Perrone F; Lastoria S; Tambaro R; Izzo F; Fiore F; Vallone P; Pignata S
Anticancer Res; 2000; 20(2B):1249-51. PubMed ID: 10810429
[TBL] [Abstract][Full Text] [Related]
13. Distribution of daunorubicin and daunorubicinol in human glioma tumors after administration of liposomal daunorubicin.
Zucchetti M; Boiardi A; Silvani A; Parisi I; Piccolrovazzi S; D'Incalci M
Cancer Chemother Pharmacol; 1999; 44(2):173-6. PubMed ID: 10412954
[TBL] [Abstract][Full Text] [Related]
14. Dual-targeting daunorubicin liposomes improve the therapeutic efficacy of brain glioma in animals.
Ying X; Wen H; Lu WL; Du J; Guo J; Tian W; Men Y; Zhang Y; Li RJ; Yang TY; Shang DW; Lou JN; Zhang LR; Zhang Q
J Control Release; 2010 Jan; 141(2):183-92. PubMed ID: 19799948
[TBL] [Abstract][Full Text] [Related]
15. What can we expect from liposomal drugs?
Dumontet C
Ann Oncol; 2001 Apr; 12(4):433-4. PubMed ID: 11398872
[No Abstract] [Full Text] [Related]
16. Early evaluation of liposomal daunorubicin (DaunoXome, Nexstar) in the treatment of relapsed and refractory lymphoma.
Richardson DS; Kelsey SM; Johnson SA; Tighe M; Cavenagh JD; Newland AC
Invest New Drugs; 1997; 15(3):247-53. PubMed ID: 9387047
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerance of liposomal daunorubicin in Kaposi sarcoma associated with human immunodeficiency virus infection.
Fournier S; Dupont B; Pialoux G; Eliaszewicz M; Gonzalez-Canali G; Feuillie V
Arch Dermatol; 1997 Jul; 133(7):918-9. PubMed ID: 9236538
[No Abstract] [Full Text] [Related]
18. [Liposomal daunorubicin (daunosom) in the treatment of recurrent acute promyelocytic leukemia].
Pivnik AV; Shtroiakovskiĭ DL; Medvedev PV; Moiseeva TN; Shklovskiĭ-Kordi NE; Skorokhod AA
Ter Arkh; 1999; 71(7):24-7. PubMed ID: 10481863
[No Abstract] [Full Text] [Related]
19. Kaposi's sarcoma: DaunoXome approved.
AIDS Treat News; 1996 May; (no 246):3-4. PubMed ID: 11363485
[TBL] [Abstract][Full Text] [Related]
20. Administration schedule of daunorubicin for elderly patients with acute myelogenous leukemia: a single-institute experience.
Dobashi N; Usui N; Yano S; Yahagi Y; Takei Y; Sugiyama K; Takahara S; Ogasawara Y; Yamaguchi Y; Saito T; Yokoyama H; Aiba K
Jpn J Clin Oncol; 2011 Jun; 41(6):820-4. PubMed ID: 21415001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
